Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the precise role of T cell factors/lymphoid enhancer-binding factor (TCFs/LEF) family members, which are the major binding complex of β-catenin, in OS is poorly understood.
|
31595984 |
2020 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNA‑873 targets HOXA9 to inhibit the aggressive phenotype of osteosarcoma by deactivating the Wnt/β‑catenin pathway.
|
30816476 |
2019 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We identified that metastatic lung OS cell lines (n = 2) exhibited increased stem cell signatures, including enhanced concomitant aldehyde dehydrogenase (ALDH1) and β-catenin expression and downstream activity, which were suppressed by Tegavivint (ALDH1: control group, mean relative mRNA expression = 1.00, 95% confidence interval [CI] = 0.68 to 1.22 vs Tegavivint group, mean = 0.011, 95% CI = 0.0012 to 0.056, P < .001; β-catenin: control group, mean relative mRNA expression = 1.00, 95% CI = 0.71 to 1.36 vs Tegavivint group, mean = 0.45, 95% CI = 0.36 to 0.52, P < .001).
|
30793158 |
2019 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
AWPPH enhances FZD7-mediated activation of Wnt/β-catenin by sponging miR-93-3p to promote OS progression.
|
31092328 |
2019 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our study indicated that macrophage-derived CCL18 promotes OS proliferation and metastasis via the EP300/UCA1/Wnt/β-catenin pathway and that CCL18 may be used as a prognostic marker and therapeutic target of OS.
|
30426155 |
2019 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The expression of nuclear FAM83H, cytoplasmic FAM83H, and β-catenin were significantly associated with each other and significantly associated with shorter survival of osteosarcoma patients by univariate analysis.
|
31215499 |
2019 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
NNT-As1 functions as a cancer-promoting lncRNA by downregulating miR-320a, thus increasing the protein expression level of beta-catenin, RUNX2 and IGF-1R as well as activation of Akt in osteosarcoma.
|
30489194 |
2019 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, miR-744 induced Wnt/β-catenin pathway and epithelial-mesenchymal transition (EMT) in OS.
|
31452740 |
2019 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibiting Wnt/β-Catenin pathway suppresses development of skeletal anomalies including enchondroma and osteosarcoma.
|
31482846 |
2019 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results will aid in elucidating the roles of miR-758 and suggest that the miR-758/HMGA1/Wnt/β-catenin pathway represents a potential therapeutic target in OS.
|
30755810 |
2019 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The purpose of this research was to investigate the effect of ginsenoside on the apoptosis and proliferation of human OS MG-63 and Saos-2 cells by regulating the expression of β-catenin.
|
30909183 |
2019 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Finally, we revealed that silybin inhibited OS cell viability by altering the protein levels of β-catenin and Runt-related transcription factor 2 (RUNX2) as determined by western blot and immunocytochemistry (ICC).
|
29068478 |
2018 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We suggest that targeting the Wnt/β-catenin pathway can eliminate CSCs populations in osteosarcoma.
|
29126913 |
2018 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
And β-catenin may be a potential therapeutic target as well as a significant prognostic marker for osteosarcoma patients in clinic.
|
29497056 |
2018 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found increased protein levels of endogenous active-β-catenin in five human osteosarcoma cell lines.
|
30613366 |
2018 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpressing circular RNA hsa_circ_0002052 impairs osteosarcoma progression via inhibiting Wnt/β-catenin pathway by regulating miR-1205/APC2 axis.
|
29852168 |
2018 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We also demonstrated that β-catenin was overexpressed in OS tissue, and that knockdown of β-catenin induced pronounced apoptosis of OS cells in the presence or absence of 17-AAG.
|
28681940 |
2018 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated the vital function of MALAT1 in the progression of OS and its potential leading mechanism, altering the expression and localization of β-catenin via epigenetic transcriptional regulation by interacting with EZH2.
|
29290771 |
2018 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, our research verified that suppression of CAT104 exerted significant inhibitory effects on osteosarcoma cell proliferation, migration, and invasion by regulating the expression of miR-381 and downstream ZEB1, as well as JNK and Wnt/β-catenin pathways.
|
29523223 |
2018 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, these findings demonstrated that the AFAP1‑AS1/miR‑4695‑5p/TCF4‑β‑catenin axis played an important role in OS progression.
|
29901121 |
2018 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CRY2 knockdown also increased the expression of matrix metalloproteinase (MMP)-2 and β-catenin, and increased OS cell proliferation and migration by inducing cell cycle progression and promoting mitogen-activated protein kinase (MAPK) and Wnt/β-catenin signaling pathways.
|
29879092 |
2018 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Up-regulated lnc-SNHG1 contributes to osteosarcoma progression through sequestration of miR-577 and activation of WNT2B/Wnt/β-catenin pathway.
|
29108989 |
2018 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Higher expression of miR-940, β-catenin, and cyclinD1 and lower SFRP1 expression were identified in OS tissues. miR-940 targeted and negatively regulated SFRP1 expression.
|
30324663 |
2018 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MiR-374a Activates Wnt/β-Catenin Signaling to Promote Osteosarcoma Cell Migration by Targeting WIF-1.
|
30523602 |
2018 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed protein levels and nuclear localization of β-catenin and RUNX2 in a panel of human osteosarcoma cell lines (SAOS, MG63, U2OS, HOS, G292, and 143B).
|
28370561 |
2017 |